Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
-
Support Care Cancer · Jul 1996
Supportive care programs in cancer at the National Cancer Center in Tokyo.
Until recently, supportive care for cancer patients in Japan was not well organized. Not too many oncologists paid attention to the improvement of daily life of patients with advanced or terminal cancer. Oncological staffs such as doctors, nurses, psychologists, and pharmacists at hospitals in Japan did not really cooperate efficiently. ⋯ At the National Cancer Center in Japan an effort is being made to expand activities in PCU, the application of Chinese acupuncture for pain relief, and the development of a virtual reality technique. A system to connect cancer centers has been established and is now being expanded to facilitate a new database on up-to-date cancer information. We have already started holding multi-institutional medical teleconferences, telepathology and teleradiology on a weekly basis, covering nine cancer centers throughout Japan.
-
Support Care Cancer · May 1996
Comparative StudyConcerns, coping and quality of life in head and neck cancer patients.
This study was conducted to explore the concerns and coping mechanisms used by patients with head and neck cancer and assess their quality of life. A group of 50 consecutive patients with oral and laryngeal cancers were interviewed using a coping and concerns checklist and a semistructured interview proforma to elicit the common concerns in relation to head and neck cancers and their surgical treatment. The Hospital Anxiety and Depression Scale was used to detect anxiety and depression. ⋯ Most subjects had numerous unresolved concerns. Mainly ineffective coping mechanisms such as helplessness and fatalism were employed leading to incomplete resolution. Interventions to minimise these concerns and to handle associated anxiety and depression would improve their quality of life.
-
Support Care Cancer · May 1996
The last 3 months of life of cancer patients: medical aspects and role of home-care services in southern Switzerland.
The clinical data on terminal cancer patients who have died since the establishment of a program of collaboration between community services and the cancer center of Canton of Ticino, southern Switzerland, were retrospectively analyzed to describe the characteristics of patients seen and the effect on them of a home-care program coordinated by the cancer center. The home-care program is based on five geographically grouped community-based domiciliary services, with the addition of one nurse responsible for coordination and one physician from the oncology center. Selection criteria for participation in the home-care program are defined. ⋯ Palliative care, provided at home through community-based domiciliary services, is associated with less frequent and shorter hospitalizations in the last 3 months of life. Medical oncology and palliative treatments should be mutually complementary to improve patients care. Cancer centers should be involved in the planning and coordination of supportive-care domiciliary services.
-
A cancer diagnosis impacts the entire family unit, but children are especially vulnerable. In the past, families and professionals did not share information or allow for children to express their feelings or to be involved. ⋯ Approaches by disease phase and developmental stage are discussed. Goals include maintaining family stability, preparing children for what may happen, allowing for flexible communication, and preventing serious psychosocial sequelae.
-
Support Care Cancer · Mar 1996
Clinical TrialDose-ranging evaluation of the antiemetic efficacy of intravenous dolasetron in patients receiving chemotherapy with doxorubicin or cyclophosphamide.
Selective 5-HT3 antagonists have proven to be safe and effective for the prevention of chemotherapy-induced nausea and vomiting. Dolasetron is a new highly selective addition to this class of antiemetics that has been shown to have significant antiemetic activity in patients receiving cisplatin-containing regimens. This pilot study was designed to evaluate the antiemetic efficacy of dolasetron in cancer patients receiving doxorubicin and/or cyclophosphamide. ⋯ Age, gender, and type of chemotherapy were significant predictors of complete antiemetic control. Adverse events were generally mild and included headache, chills, lightheadedness, fever, diarrhea, dizziness, and asymptomatic prolongation of ECG intervals. Intravenous dolasetron is safe and effective in the prevention of emesis induced by doxorubicin and/or cyclophosphamide.